ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Sjögren's Syndrome: Pathogenesis

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 1486
High Resolution HLA Analysis In Primary and Secondary Sjögren’s Syndrome
Abstract Number: 1488
Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren’s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren’s Syndrome (ASSESS) Cohort
Abstract Number: 1489
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjögren’s Syndrome
Abstract Number: 1490
Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjögren’s Syndrome Patients Versus Healthy Controls Based On RNA-Seq
Abstract Number: 1491
Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren’s Syndrome Patients
Abstract Number: 1492
Histone Deacetylase 1 But Not 2 Is Highly Expressed In The Lymphocyte Foci In The Labial Glands Of Patients With Sjogren’s Syndrome
Abstract Number: 1494
Increased Expression Of Interleukin 33 In Sera and Salivary Gland From Patients With Sjögren Syndrome
Abstract Number: 1495
Lesional Intereukin-21 Expression Correlates With Functional Germinal Center Formation and T Follicular Helper Cell Infiltration In The Salivary Glands Of Sjogren’s Syndrome
Abstract Number: 1496
DNA Methylation In Six Cell and Tissue Types In Sjögren’s Syndrome Reveals Distinct Patterns Across Samples and Clustering Based On Disease Status
Abstract Number: 1497
Endosomal TLR Triggering Of B Cells In Sjögren’s Syndrome Induces Increased Plasma Cells Differentiation, Ig Class Switch and Immunoglobulin Production
Abstract Number: 1498
Hypofunction In Intact Cell Lobules Reflect Salivary Flow Rates In Sjogren’s Patients
Abstract Number: 1499
Detection Of CD4+CD25lowGITR+ T Lymphocytes In Sjogren’s Syndrome-Interstitial Lung Disease
Abstract Number: 1500
Use Of B Lymphocyte Stimulator Inhibitor Belimumab May Be Associated With a Decrease In the Serum Concentration Of Endothelial Growth Factor In Patients With Primary Sjögren’s Syndrome
Abstract Number: 1501
Umbilical Cord Mesenchymal Stem Cells Inhibit The Generation Of T Follicular Helper Cell In Sjogren’s Syndrome
Abstract Number: 1502
Antibodies To Anti-Type -3 Muscarinic Acetylcholine Receptor Are Highly Prevalent To Rabbits Immunized With 4-Hydroxy-2-Noneal-Modified and 60-Kda Ro
Abstract Number: 1503
The Suppressive Ability Of Altered Peptide Ligands To M3R Reactive T Cells In M3R Induced Autoimmune Sialadenitis
Abstract Number: 1504
Anti-Inflammation Effect Of Peroxisome Proliferator-Activated Receptor-ã (PPAR-ã) In Non-Obese Diabetic Mice With Sjogren’s Syndrome

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology